Deals & Corporate Governance

  • July 11, 2025

    Quinn Emanuel Sanctioned For Ad Case 'Misrepresentations'

    A California federal judge imposed almost $3 million in sanctions on Quinn Emanuel Urquhart & Sullivan LLP for what he called the firm's "deliberate misrepresentations" concerning an expert witness in a false advertising suit between medical testing company Guardant Health and rival Natera.

  • July 11, 2025

    Drugmaker Fights Claims Over 'Misleading' IPO Statements

    Investors in biopharmaceutical company BioAge Labs Inc. mischaracterized certain statements the company made in an effort to allege securities fraud after the company hit the brakes on a clinical trial for its lead product candidate, the company has argued.

  • July 09, 2025

    Suit Challenges Colo. Abortion Parental Notice Law

    An OB-GYN asked a Colorado state judge on Tuesday to block the state's requirement for minors seeking an abortion to give notice to a parent, saying it runs afoul of a 2024 amendment to the Colorado Constitution.

  • July 09, 2025

    End Of USAID Program Dooms HIV Funding Case, Judge Says

    The U.S. Agency for International Development's cancellation of a funding opportunity to fight HIV and tuberculosis in South Africa ended a lawsuit alleging that the desired services should have been sought through a contract procurement, a U.S. Court of Federal Claims judge has ruled.

  • July 08, 2025

    IRhythm Argues Patent Owner's Inaction Shouldn't Doom IPRs

    A heart monitoring company told the acting U.S. Patent and Trademark Office director that it shouldn't be barred from challenging a patent just because the company had known about it for 12 years, especially when the owner didn't assert it during that time.

  • July 08, 2025

    Calif.'s PE Healthcare Oversight Bill: 3 Things To Know

    A California bill expanding the power of a state healthcare affordability board is moving through the Legislature amid opposition from key industry organizations. Here, Law360 Healthcare Authority examines three key aspects of the legislation.

  • July 08, 2025

    Masimo Criticizes Bid To DQ Quinn Emanuel In Payout Suit

    Masimo Corp. is fighting a bid by its former CEO Joe Kiani to disqualify Quinn Emanuel Urquhart & Sullivan LLP from representing the medical technology company in Delaware Chancery Court litigation over Kiani's quest for a $450 million payout.

  • July 07, 2025

    Kirkland-Led Zenyth Partners Raises $375M For Latest Fund

    Kirkland & Ellis LLP-advised private equity shop Zenyth Partners on Monday announced that it closed its second flagship fund after securing $375 million in capital commitments, which will be used to invest in healthcare services-focused companies.

  • July 03, 2025

    The Firms That Won Big At The Supreme Court

    The number of law firms juggling three or more arguments before the U.S. Supreme Court this past term nearly doubled from the number of firms that could make that claim last term.

  • July 03, 2025

    Breaking Down The Vote: The High Court Term In Review

    The U.S. Supreme Court once again waited until the term's closing weeks — and even hours — to issue some of its most anticipated and divided decisions.

  • July 02, 2025

    The Biggest Patent Rulings Of 2025: A Midyear Report

    A ruling by the full Federal Circuit invited greater scrutiny of patent damages testimony, and the U.S. Patent and Trademark Office's acting director established new criteria for rejecting patent challenges. Here's a look at the top patent decisions from the first half of 2025.

  • July 01, 2025

    Alnylam Pharma Beats Inventorship Suit Tied To COVID-19 Jab

    A Delaware federal judge Tuesday tossed Acuitas Therapeutics' lawsuit seeking to have its scientists added as inventors on seven Alnylam Pharmaceuticals patents tied to mRNA technology, saying the complaint doesn't plausibly allege the scientists have a financial or reputational interest in the outcome of the litigation.

  • July 01, 2025

    Healthcare Deals That Shaped 2025: Midyear Highlights

    As 2025 hits its midyear point, Law360 Healthcare Authority asked attorneys for their top choices for influential deals that have helped shape the healthcare industry so far this year.

  • June 30, 2025

    Fed. Circ. Faults PTAB Ax Of Patent On Bausch Eye Drops

    The Federal Circuit ruled Monday that the Patent Trial and Appeal Board wrongly invalidated all the claims of a patent that Bausch & Lomb licenses for its Lumify eye drops, saying the board used an incorrect claim construction when siding with generics maker Slayback Pharma.

  • June 26, 2025

    Biotech Co. Must Face Investor Suit Over Misleading Claims

    Biotech company CytoDyn and its former executives and directors cannot escape a suit accusing them of misleading shareholders about the likelihood that the U.S. Food and Drug Administration would approve its drug the company claimed had the potential to treat HIV and COVID-19.

  • June 26, 2025

    Under The Radar: Bankruptcy News You May Have Missed

    The U.S. Trustee's Office opposed Prospect Medical's Chapter 11 plan disclosure on the grounds that the plan can't be confirmed because of its release provisions; hospital operator Steward Health Care's former captive insurer appealed a bankruptcy judge's decision to OK a settlement Steward struck with secured lenders; and Celsius Network asked a federal judge to let its lawsuit targeting blockchain analysis company Chainalysis Inc. continue.

  • June 26, 2025

    Ga. Panel Affirms $6.5M Verdict, $1.8M Fees Over Brain Injury

    A Georgia appellate panel said Thursday that a woman who said she was left permanently disabled while recovering from knee replacement surgery can keep her $6.5 million verdict, along with $1.8 million in attorney fees, ruling that neither award was unreasonable in the medical malpractice suit.

  • June 26, 2025

    Judge Tosses Biogen MS Drug Antitrust Suit, For Now

    An Illinois federal court tossed a proposed class action accusing Biogen of reducing competition for its multiple sclerosis drug Tecfidera through payments to pharmacy benefit managers, after finding that only some drug pricing lists would have been affected.

  • June 24, 2025

    Healthcare Deals This Week: Sanofi, Abridge, Royalty Pharma

    The past week marked a busy period for dealmaking in the healthcare industry, with major partnerships and M&A announcements from companies like Royalty Pharma, Sanofi and Otsuka.

  • June 24, 2025

    AI Healthcare Startup Abridge Raises $300M Series E

    Generative artificial intelligence company Abridge has raised $300 million in a fresh round of capital, the company announced Tuesday.

  • June 24, 2025

    Cataract Surgery Tech Co. Secures $125M Series B Funding

    Ophthalmic robotic surgery company ForSight Robotics on Tuesday revealed that it completed fundraising for its Series B financing round after securing $125 million from investors.

  • June 24, 2025

    A Midyear Review: Healthcare Dealmaking Trends Of 2025

    Law360 Healthcare Authority reviews key trends that helped shape dealmaking activity in the healthcare industry so far this year.

  • June 24, 2025

    Goodwin Procter Adds PE Firm General Counsel In NY

    Goodwin Procter LLP has added the former general counsel of private equity firm Gurnet Point Capital to bolster its life sciences and healthcare practice groups.

  • June 23, 2025

    Teladoc Says Investor Suit Over User Losses Is 'Illogical'

    Telemedicine giant Teladoc Health Inc. and two of its executives seek to shed a proposed investor class action, telling a New York federal judge the shareholder suit makes "illogical" claims that they lied about post-pandemic increases in customer acquisition costs for the company's flagship mental health counseling platform.

  • June 20, 2025

    Ga. Panel Says Suit To Collect $12.1M Judgment Too Late

    The Georgia Court of Appeals on Friday said a trial court rightly found Mariner Healthcare Management Co.'s lawsuit against Sovereign Healthcare LLC over the recovery of a $12.1 million judgment was barred by the state's four-year statute of limitations for fraud.

Expert Analysis

  • SBA Proposal Materially Alters Contractor Recertification

    Author Photo

    The Small Business Administration's new proposed rule on recertification affects eligibility for set-aside contracts, significantly alters the landscape for mergers and acquisitions in the government contracts industry, and could have other unintended downstream consequences, says Sam Finnerty at PilieroMazza.

  • Firms Must Offer A Trifecta Of Services In Post-Chevron World

    Author Photo

    After the U.S. Supreme Court’s Loper Bright Enterprises v. Raimondo decision overturning Chevron deference, law firms will need to integrate litigation, lobbying and communications functions to keep up with the ramifications of the ruling and provide adequate counsel quickly, says Neil Hare at Dentons.

  • Del. Dispatch: Director Caremark Claims Need Extreme Facts

    Author Photo

    The Delaware Court of Chancery recently dismissed Caremark claims against the directors of Centene in Bricklayers Pension Fund of Western Pennsylvania v. Brinkley, indicating a high bar for a finding of the required element of bad faith for Caremark liability, and stressing the need to resist hindsight bias, say attorneys at Fried Frank.

  • PE Firms Should Prepare For Increased False Claims Scrutiny

    Author Photo

    The impact private equity firms may have over medical decisions and care is increasingly attracting potential liability under the False Claims Act and attention from states and the federal government, so investors should follow best practices including conducting due diligence both before and after acquisitions, say attorneys at K&L Gates.

  • Unpacking HHS' Opinion On Cell Therapy Refund Programs

    Author Photo

    A recent advisory opinion from the U.S. Department of Health and Human Services, determining that a biopharma company's refund program for its cell therapy will not be penalized, indicates an encouraging willingness to engage, but the regulator's assumptions about the program's limited term warrant a closer look, says Mary Kohler at Kohler Health.

  • How 5 States' Deal Notification Laws Are Guiding Healthcare

    Author Photo

    Healthcare transaction notification laws at various stages of implementation in California, Illinois, Indiana, Oregon and Washington are shaping sector mergers and acquisitions, with significant transparency, continuity of care and compliance implications as providers tackle complex regulatory requirements, says Melesa Freerks at DLA Piper.

  • The Good, The Bad And The Ugly Of Healthcare's PE Boom

    Author Photo

    While an influx of capital may provide access to new resources and innovative technologies, the private equity model's method of funding may be fundamentally at odds with patient-first healthcare, and in recent years that inherent tension has gotten ugly, say Eva Gunasekera and Jaclyn Tayabji at Tycko & Zavareei.

  • High Court Made Profound Mistake In Tossing Purdue Deal

    Author Photo

    The U.S. Supreme Court's recent decision to throw out Purdue Pharma's Chapter 11 plan jeopardizes a multistate agreement that would provide approximately $7 billion in much-needed relief to help fight the opioid epidemic, with states now likely doomed to spend years chasing individual defendants across the globe, says Swain Wood at Morningstar.

  • After Chevron: Scale Tips Favor Away From HHS Agencies

    Author Photo

    The loss of Chevron deference may indirectly aid parties in challenging the U.S. Department of Health and Human Services' interpretations of regulations and could immediately influence several pending cases challenging HHS on technical questions and agency authority, say attorneys at Ropes & Gray.

  • After Chevron: FDA Regulations In The Crosshairs

    Author Photo

    The U.S. Supreme Court's overturning of the Chevron doctrine is likely to unleash an array of challenges against the U.S. Food and Drug Administration, focusing on areas of potential overreach such as the FDA's authority under the Federal Food, Drug and Cosmetic Act, say attorneys at Debevoise.

  • Navigating Scrutiny Of Friendly Professional Corps. In Calif.

    Author Photo

    In light of ongoing scrutiny and challenges to private equity participation in the California healthcare marketplace, particularly surrounding the use of the friendly professional corporation model, management services organizations should consider implementing four best practices, say attorneys at Holland & Knight.

  • Class Actions At The Circuit Courts: June Lessons

    Author Photo

    In this month's review of class action appeals, Mitchell Engel at Shook Hardy considers two recent decisions from the Third and Tenth Circuits, and identifies practice tips around class action settlements and standing in securities litigation.

  • The Current State Of Healthcare Transaction Reviews In Calif.

    Author Photo

    As of April, certain healthcare transactions in California have been subject to additional notification compliance requirements, and complying with these new rules could significantly delay and discourage some deals, says Andrew Demetriou at Husch Blackwell.